A Phase 1/2 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bayer Healthcare Pharmaceuticals Inc
Start Date
July 19, 2021
End Date
February 1, 2023
Administered By
Duke Cancer Institute
Awarded By
Bayer Healthcare Pharmaceuticals Inc
Start Date
July 19, 2021
End Date
February 1, 2023